Company news

Arbutus Biopharma Corporation news in 2024

Arbutus Biopharma Corporation's news releases, calls and decks from 2024, newest first.

View company

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

November 25, 2024

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

November 14, 2024

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

November 14, 2024

Arbutus to Present at Jefferies London Healthcare Conference

November 13, 2024

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 5, 2024

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

October 22, 2024

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

October 14, 2024

Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

September 30, 2024

Arbutus to Participate in Two Upcoming Investor Conferences

September 2, 2024

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

July 31, 2024

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

July 17, 2024

Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

June 5, 2024

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

June 5, 2024

Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

June 4, 2024

Arbutus to Participate in Jefferies Global Healthcare Conference

May 28, 2024

Arbutus to Present Imdusiran Data at EASL Congress 2024

May 21, 2024

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

May 1, 2024

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

April 17, 2024

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

April 3, 2024

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

February 28, 2024

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

February 14, 2024

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

January 7, 2024

Calls in 2024

Decks in 2024